Trial reportEuropean journal of clinical pharmacology2018
Subcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers.
Trial report in European journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02724098 (Bioavailability of Subcutaneously Given Dexmedetomidine in Healthy Volunteers), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bioavailability of Subcutaneously Given Dexmedetomidine in Healthy Volunteers
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Intranasal Dexmedetomidine for Pain Management in Older Patients: A Cross-Over, Randomized, Double-Blinded, Active-Controlled Trial.Drugs & aging · 2023Trial
- Population Modelling of Dexmedetomidine Pharmacokinetics and Haemodynamic Effects After Intravenous and Subcutaneous Administration.Clinical pharmacokinetics · 2020Trial
- Effects of intravenous infusion of lidocaine and dexmedetomidine on inhibiting cough during the tracheal extubation period after thyroid surgery.BMC anesthesiology · 2019Trial
- Development and Validation of a Chinese Obesity-Specific Physiological Database for PBPK Modeling.Clinical pharmacokinetics · 2026Article
- Dexmedetomidine Dosing Strategies in Sedation and Anesthesia: Pharmacokinetics, Safety, and Clinical Applications - A Narrative Review.Drug design, development and therapy · 2026Review
- Investigation and Clinical Experience With Subcutaneous Dexmedetomidine: An Educational Focused Review With a Focus on Pediatric-Aged Patients.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- Refractory symptoms and end of life midazolam use in cancer patients, a single center experience.Palliative & supportive care · 2025Article
- Article
- Comparison the Effects of Two Different Doses of Dexmedetomidine and Propofol on Intraoperative Sedation; Hemodynamic Changes and Postoperative Complications in Patients Undergoing Ovarian Puncture Surgery.Advanced biomedical research · 2025Article
- Dexmedetomidine Versus Midazolam for End-of-Life Sedation and Agitation: Protocol for a Randomized Controlled Trial (The DREAMS Trial).JMIR research protocols · 2024Article
- Pharmacokinetics of dexmedetomidine in anaesthetized horses following repeated subcutaneous administration and intravenous constant rate infusion.BMC veterinary research · 2023Article
- Design, Synthesis, and Bioevaluation of Dexmedetomidine Prodrug.ACS medicinal chemistry letters · 2023Article
- Emergency Palliative Cancer Care: Dexmedetomidine Treatment Experiences-A Retrospective Brief Report on Nine Consecutive Cases.Pain and therapy · 2023Article
- Prophylactic Treatment of Intestinal Ischemia-Reperfusion Injury Reduces Mucosal Damage and Improves Intestinal Absorption.Journal of inflammation research · 2023Article
- Use of dexmedetomidine repeated subcutaneous administration for balanced anaesthesia in horses.BMC veterinary research · 2022Article
- Dexmedetomidine-mediated sleep phase modulation ameliorates motor and cognitive performance in a chronic blast-injured mouse model.Frontiers in neurology · 2022Article
- Hemodynamic and respiratory effects of dexmedetomidine sedation in critically ill Covid-19 patients: A retrospective cohort study.Acta anaesthesiologica Scandinavica · 2021Article
- Feasibility of Intranasal Dexmedetomidine in Treatment of Postoperative Restlessness, Agitation, and Pain in Geriatric Orthopedic Patients.Drugs & aging · 2021Article
- Dexmedetomidine: What's New for Pediatrics? A Narrative Review.Journal of clinical medicine · 2020Review
- Adding Dexmedetomidine to Articaine Increases the Latency of Thermal Antinociception in Rats.Anesthesia progress · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
purposePalliative care patients often need sedation to alleviate intractable anxiety, stress, and pain. Dexmedetomidine is used for sedation of intensive care patients, but there is no prior information on its subcutaneous (SC) administration, a route that would be favored in palliative care. We compared the pharmacokinetics and cardiovascular, sympatholytic, and sedative effects of SC and intravenously (IV) administered dexmedetomidine in healthy volunteers.
methodsAn open two-period, cross-over design with balanced randomization was used. Ten male subjects were randomized to receive 1 μg/kg dexmedetomidine both IV and SC. Concentrations of dexmedetomidine and catecholamines in plasma were measured. Pharmacokinetic variables were calculated with non-compartmental methods. In addition, cardiovascular and sedative drug effects were monitored.
resultsEight subjects completed both treatment periods. Peak concentrations of dexmedetomidine were observed 15 min after SC administration (median; range 15-240). The mean bioavailability of SC dexmedetomidine was 81% (AUC
conclusionsDexmedetomidine is relatively rapidly and efficiently absorbed after SC administration. Subcutaneous dexmedetomidine may be a feasible alternative in palliative sedation, and causes attenuated cardiovascular effects compared to IV administration. CLINICALTRIALS. GOV IDENTIFIER: NCT02724098 . EUDRA CT number 2015-004698-34 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.